Allergan announced that the FDA has approved an additional indication for Botox Cosmetic (onabotulinumtoxinA) to temporarily treat moderate-to-severe lateral canthal lines, also known as “crow’s feet” lines. Botox Cosmetic is the first of its kind approved for this indication.
The safety and efficacy of Botox Cosmetic as treatment for crow’s feet lines was demonstrated in two randomized, multi-center, placebo-controlled clinical trials. The studies enrolled more than 1,350 subjects with 833 subjects receiving Botox Cosmetic. Results showed that Botox Cosmetic was an effective treatment compared to the control group.
Botox Cosmetic is a neuromuscular blocker that works by blocking nerve impulses and reducing movement to the muscles around the eye area. The decreased muscle activity helps reduce the appearance of crow’s feet lines for noticeable results that do not radically change facial appearance.
Botox is also indicated for prophylaxis of headaches in adults with chronic migraine, severe primary axillary hyperhidrosis when topical agents are inadequate, treatment of upper limb spasticity in the flexor muscles of the elbow, wrist and finger in patients ≥18yrs, cervical dystonia in patients ≥16yrs, to reduce severity of abnormal head position and neck pain, strabismus or blepharospasm related to dystonia in patients ≥12yrs, and urinary incontinence due to detrusor overactivity associated with a neurologic condition (eg, spinal cord injury, multiple sclerosis) in adults who have an inadequate response to or are intolerant of an anticholinergic drug.
For more information call (800) 433-8871 or visit BotoxCosmetic.com.